Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Finalizes Guidance On Early-Stage Clinical Trials

This article was originally published in The Gray Sheet

Executive Summary

FDA released final guidance on granting investigational device exemptions for early feasibility medical device clinical studies Oct. 1. It grants manufacturers additional flexibility to change the clinical protocol in early feasibility trials, which are often conducted as the device’s design is still being finalized.

You may also be interested in...



4C Medical Plans First Early Feasibility Study For An Implantable In Japan

4C Medical plans to conduct both an early feasibility study and the pivotal trial for its mitral regurgitation treatment device simultaneously in Japan, the US and Canada. The company says the study is the first early feasibility study in Japan for an implantable device.

Blueprint For Early Feasibility Studies: MDIC Hopes To Increase US Activity

While more early feasibility studies for devices are being conducted in the US in response to FDA reforms, small firms are still facing complications. Now a draft blueprint from the public-private Medical Device Innovation Consortium seeks to make the process more straightforward.

FDA Device Center Touts Clinical Trial Review Performance

According to the latest numbers, CDRH says it has reduced median investigational review exemption review times to 30 days, and three out of four IDEs are now fully approved after two review cycles.

Related Content

Topics

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel